Utilization of serology for the diagnosis of suspected Lyme borreliosis in Denmark: Survey of patients seen in general practice by Dessau, Ram B et al.
RESEARCH ARTICLE Open Access
Utilization of serology for the diagnosis of
suspected Lyme borreliosis in Denmark: Survey
of patients seen in general practice
Ram B Dessau
1*, Jette M Bangsborg
2, Tove Ejlertsen
3, Sigurdur Skarphedinsson
4, Henrik C Schønheyder
3
Abstract
Background: Serological testing for Lyme borreliosis (LB) is frequently requested by general practitioners for
patients with a wide variety of symptoms.
Methods: A survey was performed in order to characterize test utilization and clinical features of patients
investigated for serum antibodies to Borrelia burgdorferi sensu lato. During one calendar year a questionnaire was
sent to the general practitioners who had ordered LB serology from patients in three Danish counties (population
1.5 million inhabitants). Testing was done with a commercial ELISA assay with purified flagella antigen from a
Danish strain of B. afzelii.
Results: A total of 4,664 patients were tested. The IgM and IgG seropositivity rates were 9.2% and 3.3%,
respectively. Questionnaires from 2,643 (57%) patients were available for analysis. Erythema migrans (EM) was
suspected in 38% of patients, Lyme arthritis/disseminated disease in 23% and early neuroborreliosis in 13%. Age 0-
15 years and suspected EM were significant predictors of IgM seropositivity, whereas suspected acrodermatitis was
a predictor of IgG seropositivity. LB was suspected in 646 patients with arthritis, but only 2.3% were IgG
seropositive. This is comparable to the level of seropositivity in the background population indicating that Lyme
arthritis is a rare entity in Denmark, and the low pretest probability should alert general practitioners to the
possibility of false positive LB serology. Significant predictors for treating the patient were a reported tick bite and
suspected EM.
Conclusions: A detailed description of the utilization of serology for Lyme borreliosis with rates of seropositivity
according to clinical symptoms is presented. Low rates of seropositivity in certain patient groups indicate a low
pretest probability and there is a notable risk of false positive results. 38% of all patients tested were suspected of
EM, although this is not a recommended indication due to a low sensitivity of serological testing.
Background
Lyme borreliosis (LB) is a diagnosis frequently consid-
ered in general practice and a large number of samples
are submitted to the diagnostic laboratory for serological
testing. The use of antibody testing in populations with
low pretest probability is cause for concern[1,2]. The
aim of this study was to describe the utilization of sero-
logical testing for Borrelia burgdorferi sensu lato includ-
ing IgG and IgM serum antibodies in general practice in
Denmark. Information on the clinical spectrum of
patients and the rates of positive and negative serologi-
cal results reported in this study may assist the general
practitioners in assessing the laboratory reports. To our
knowledge, data about the utilization of LB serology in
general practice and the clinical characteristics of both
seropositive and seronegative patients has not been pub-
lished previously.
Methods
A survey was performed in three Danish counties
(Copenhagen, Funen and North Jutland, total population
1.47 million) of patients with LB serology being
requested by a general practitioner or a practicing spe-
cialist. In each county LB serology was performed in
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pital. Thus, the study was based on the entire popula-
tion in the three counties. During one full year from
March 2001 to February 2002 a questionnaire was
included with the LB serology report sent to general
practitioners and practising specialists. 694 patients were
excluded because they were subsequently referred to a
hospital department and tested for intrathecal antibody
production. The doctors were asked to classify the clini-
cal manifestation of each patient according to the seven
EUCALB case-definitions, which were printed on the
backside of the questionnaire[3]. Indication of “various
other symptoms” and “no current symptoms” was also
an option.
Laboratory methods
All three laboratories used the same commercial assay
f o rm e a s u r e m e n to fI g Ga n dI g Ms e r u ma n t i b o d i e s
(IDEIA™, Oxoid, Cambridge, UK) which is based on pur-
ified flagella antigen from a Danish strain of B. afzelii.
The assay was performed according the protocol from
the manufacturer. Grey zone results were considered
negative. The cut-off values of the test were from the
outset adjusted by the manufacturer to be 98% specific
in a healthy Danish blood-donor population for both
IgM and IgG antibodies[4]. The specificity did not
change over time as confirmed by recent testing of
healthy Danish blood donors living in an endemic area
in Zealand[5]. According to the literature, the diagnostic
sensitivities for IgG/IgM antibodies are 36%/48% in
erythema migrans (EM), 77%/57% in early neuroborre-
liosis (NB) and 100%/12% in acrodermatitis chronica
atrophicans[4,6-8]. The results of all serological samples
were retrieved from the departments’ laboratory infor-
mation systems. Patients were identified by the unique
Danish civil registration number and each sample was
coded with a unique number and an identifier for the
general practitioner.
Statistical methods
From patients with repeat samples only the first sample
was included in the analysis. The rate of seropositivity
was chosen as dependent variable in statistical analyses
of the diagnostic yield in different groups of patients
according to clinical symptoms, season, reported tick
bite, county, sex and age groups. The chi-square test
was used for 2 × 2 tables (p values < 0.05 were consid-
ered significant). 95% confidence intervals (CI) on the
binomial probability were calculated by the Wilson
method. A generalized additive model (i.e. a non-linear
model) was used for logistic regression due to the non-
linear characteristics of the seasonal variation[9]. All
analyses were performed with “R” statistical software
[10]. See appendix for further details.
Ethics
The Danish Registry Board (record 2001-41-0617)
approved the study according to guidelines for registry-
based research.
Results
A total of 4,664 patients seen in general practice had LB
serology performed.
Thus, the incidence of testing for LB was 267 per
100,000 per year. 427 (9.2%, CI 8.4-10.0%, Wilson)
patients were IgM antibody positive and 155 (3.3%, CI
2.8-3.9%, Wilson) were IgG antibody positive.
Response rate
2,643 (57%) questionnaires were returned by 627 general
practitioners. A possible selection bias was evaluated by
logistic regression with data from the laboratory infor-
mation systems. Compared to the other age groups the
response rate was lower for the age group 16 to 50
years old (54%, OR 0.83, CI 0.73-0.94). The response
rate was related neither to sex nor season. The IgG ser-
opositivity rate was 3.4% for the patients included versus
3.2% for those not included (chi-square p = 0.66). How-
ever, the IgM seropositivity rate was 10.4% for the
patients included and 7.5% for those not included (chi-
square p = 0.0013).
Clinical manifestations in patients tested for LB
A rash (suspected to be EM) was seen in 1,011 (38%) of
the patients (Table 1). Lyme arthritis was suspected in
603 (23%) patients and neurological symptoms were
recorded in 340 (13%) patients.
Rates of seropositivity and treatment
IgM and IgG seropositivity rates and rates of treatment
for LB are shown in Table 1 and Figure 1 for the 2,643
patients with clinical data. IgM seropositivity rates were
found to be elevated in children (21%, OR 2.3) and
patients with a rash (17.2%, OR 3.3). The IgG seroposi-
tivity rate was high in the 67 patients suspected of acro-
dermatitis (10.4%, OR 3.6). A low rate of IgG antibody
(2%, OR 0.4) and IgM antibody (7.2%, OR 0.5) was
found in patients reporting an “insect bite” instead of a
tick bite. The lowest IgG seropositivity rate (1.8%, OR
0.4) was found in patients aged 16-50 years. In patients
with a rash 19.4% was IgG or IgM antibody positive.
There was a distinct seasonal variation in testing activ-
ity (Figure 1A) with a trough of 70 patients in March
and a peak of 527 patients in August. However, the
non-linear analysis showed fairly constant rates of sero-
positivity throughout the year with a tendency towards
higher rates in the autumn and a trough in April; this
variation was statistically significant only for IgM anti-
bodies (Figure 1C).
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all the patients. Higher treatment rates were found in
patients with tick bites (34.9%, OR 2.9) and patients
with a rash (44.9%, OR 7.2).
Tick bite and rash
In patients with a rash the rate of IgM seropositivity was
the same (19%) whether they reported a tick bite or not
(Table 2). However, in patients with a rash and a tick
bite 56% were treated compared to 36% of the group
with no bite reported. In patients where “other insect
bite” was indicated only 10% were IgM positive.
Discussion
This study provides information on the clinical mani-
festations of patients with LB serology testing in gen-
eral practice in Denmark. The rates of seropositivity
presented thus represent a mixture of patients with
active Borrelia infection, immunological memory or
non-specific cross-reactivity. In more than one third of
the patients EM was suspected and these patients
received antibiotic therapy also when antibody findings
were negative. This is in agreement with the percep-
tion that EM with a characteristic presentation or his-
tory of an expanding rash is a distinct clinical entity
and that laboratory testing is unnecessary and of lim-
ited utility[1,11].
The average rate of IgG antibodies was low (3.4%)
with a tendency to be even lower in patients suspected
of Lyme arthritis (2.3%) and chronic NB (1.5%) which
comes very close to the expected background seroposi-
tivity of 2%. This indicates a large proportion of false
positive results and a pretest probability lower than
recommended[12].
High IgM seropositivity rates were found in patients
with suspected EM and in children (17.2 and 21.0%,
Table 1 Main results and rates of seropositivity
Variable Category N IgG positive IgM positive Treated
% OR(95%CI) % OR(95%CI) % OR(95%CI)
Total 2643 3.4 10.4 21.1
1N = 2569
Age group 0-15 years 195 3.1 0.60(0.25-1.44) 21.0 2.29(1.52-3.47) 24.3 0.84(0.55-1.3)
16-50 years 1162 1.8 0.39(0.23-0.65) 9.0 1.01(0.76-1.34) 18.3 0.96(0.76-1.2)
>50 years 1286 4.8 reference 10.0 reference 23.2 reference
Sex Female 1509 3.1 reference 10.1 reference 21.5 reference
Male 1134 3.7 1.23(0.79-1.91) 10.7 1.00(0.77-1.30) 20.6 0.90(0.72-1.1)
Reported tick bite No bite 1468 3.3 reference 9.2 reference 12.0 reference
2“Insect bite” 346 2.0 0.42(0.18-0.97) 7.2 0.50(0.32-0.79) 26.8 1.36(0.98-1.9)
Tick bite 829 4.0 0.88(0.54-1.44) 13.6 1.05(0.79-1.47) 34.9 2.9(2.2-3.7)
3Exposure Low 167 1.2 0.39(0.09-1.70) 6.0 0.81(0.40-1.63) 21.1 0.54(0.27-1.1)
Normal 2153 3.2 reference 10.7 reference 22.1 reference
High 323 5.6 1.59(0.89-2.83) 10.2 0.95(0.63-1.43) 7.9 0.90(0.64-1.3)
Suspected Lyme disease manifestation
4
Rash 1011 4.7 1.82(0.95-3.47) 17.2 3.30(2.22-4.89) 44.9 7.2(5.0-10)
Early neuroborreliosis 340 2.4 0.88(0.36-2.15) 6.2 0.95(0.55-1.63) 7.7 0.72(0.44-1.2)
Lymphocytoma 28 0 7.1 0.65(0.13-3.13) 17.9 1.80(0.62-5.3)
Carditis 14 0 21.4 3.66(0.93-14.35) 23.1 1.90(0.41-8.7)
Arthritis 603 2.3 0.79(0.37-1.66) 6.6 0.97(0.63-1.52) 8.4 0.63(0.42-0.94)
Acrodermatitis 67 10.4 3.20(1.24-8.25) 10.4 1.42(0.61-3.28) 13.6 0.93(0.42-2.1)
Chronic Neuroborreliosis 130 1.5 0.54(0.25-1.18) 5.4 0.87(0.45-1.69) 5.5 0.57(0.24-1.35)
Various 330 1.5 0.52(0.19-1.44) 6.7 0.91(0.53-1.56) 7.8 0.63(0.38-1.1)
No current clinical symptoms 367 3.8 1.22(0.61-2.46) 9.5 1.21(0.78-1.87) 8.3 0.38(0.24-0.60)
Characteristics of 2,643 patients tested for Borrelia antibodies. The table includes the rates of seropositivity for IgG and IgM, the percent of patients treated with
antibiotics, and the corresponding odds ratios for the three multivariate logistic regression models.
Statistically significant odds ratios (OR) with 95% Confidence Intervals (CI) not including “one” are highlighted with bold.
1Missing information about treatment from 74 patients.
2This option was called “other insect bite” on the questionnaire.
3Exposure was proposed as High if the patient was a farmer, forest worker and hunter or other patients with similar outdoor activities. Low exposure was
proposed as a “person in rare contact with nature”. All others were considered “normal”.
4More than one symptom was registered for some patients. Categories for each symptom are “present” with “absent” as reference. The table has been shortened
by omitting the% IgG positive,% IgM positive and% Treated for the patients when the respective symptom(s) are absent. These percentages were similar to the
total average% positive/treated at the top of the table.
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found in patients with suspected acrodermatitis.
Validity of the survey
The response rate for the clinical survey was 57% and
there is a possibility of selection bias. However, we had
access to descriptive data on all patients through the
laboratory information systems of the participating
departments. It was noted that compared to patients not
included there were fewer patients aged 16-49 years in
the study group and the rate of IgM seropositivity was
slightly higher. Whether this reflected a selection bias
for certain clinical manifestations is not known and
overestimation of the seropositivity rate in some of the
clinical subgroups is possible. From a methodological
point of view, it would be desirable if the questionnaire
had been completed during the first consultation with
the patient, this being so before the serological results
Figure 1 Seasonal characteristics of test utilization and treatment for Lyme borreliosis.F o u rg r a p h sA ,B ,C ,Di no n ef i g u r e .T h e
smoothed logistic regression curve with 2 standard errors above and below the estimate shows the seasonal variation in the proportion of
patients who are IgG antibody positive, IgM antibody positive or treated for Lyme disease. The horizontal line at zero indicates the mean
number. Months of the year are abbreviated by the first letter.
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patients was not materially influenced by the laboratory
report. Altogether, there seems to have been a prefer-
ence for inclusion of IgM positive patients and the sero-
positivity rates and OR for IgM antibody results shown
in Table 1 are likely to be marginally too high.
Seropositivity rates and the clinical variables
The overall rate of seropositivity in our study compares
well with another Danish study of 897 consecutive sam-
ples obtained during the winter months, December to
April, where 9.9% were IgM and 2.0% were IgG positive
using the same flagella based assay[13].
In the present study 829 (31%) of the tested patients
reported a tick-bite. This is a much lower rate than seen
in a Swedish survey of patients with reported LB. In this
s t u d y7 9 %o ft h ep a t i e n t sw e r ea w a r eo fat i c kb i t ep r e -
ceding the onset of symptoms[14]. This disparity may
be explained by the difference in populations studied, as
only patients with a reported diagnosis of LB were
included in the Swedish study. Our study confirms that
a history of a tick bite is not only a frequent cause for
serological testing, but also an important motivation for
the prescription of antibiotic therapy. Still, it has been
shown that only about 0.5% of tick bites lead to clinical
LB[15].
Tick bites were a fairly common complaint in our
study (13.6% of patients). This was also shown in a
Dutch study that reported an annual number of 4.6
patients with tick bites compared to only 0.9 patient
with an EM diagnosis per doctor (average practice
population 2430 people)[16]. Furthermore, reports from
the USA indicate that a tick bite may lead to costly and
unnecessary serologic testing or prophylactic antibiotic
therapy[17,18].
When our patients reported a tick bite it was most
likely due to Ixodes ricinus and not a non specified
“insect-bite” as other arthropods in Denmark do not
remain attached to the skin for a longer period and has
to be removed. This could explain why patients with
“other insect bites” were less frequently found to be IgM
and IgG antibody positive (Tables 1 and 2). More than
one third (38%) of the tests were requested from
patients with a rash, although this is not generally
recommended due to the relatively low sensitivity of
antibody testing in this group[3,7,19] and the clinical
diagnosis is considered to be reliable [20,21]. Treatment
was given to 44.9% of patients with a rash. The rate of
seropositivity for either IgG or IgM antibodies was
19.4%, indicating that the decision to treat was based on
a sensible clinical evaluation.
It is recommended to perform a lumbar puncture
when NB is suspected[3,19,22]. In our study 340
patients with suspected early NB and 130 with suspected
chronic NB were not further investigated with a lumbar
puncture and testing for intrathecal antibody produc-
t i o n .A sa b o u t2 0 %o fp a t i e n t sw i t he a r l yN Bm a yb e
seronegative[23], some cases might have been over-
looked. However, we cannot preclude that some patients
may have been referred to neurological evaluation, but a
specialist did not deem testing for intrathecal antibody
production relevant after evaluation.
Concerning possible stage 3 LB a high sensitivity of
IgG antibodies is expected. Judged on the rate of IgG
seropositivity in the group of patients with suspected
acrodermatitis the doctors were conscious of this entity.
But when using serology to support the diagnosis of
Lyme arthritis the main problem was the low prevalence
of this disease in the tested population. Only 2.3% of
patients suspected of arthritis were found to be IgG
positive in the present study (Table 1). This rate is close
to the level of reactivity in the healthy adult population.
Thus, in some subgroups there are few true cases of LB
and the rate of seropositivity is close to the healthy
background population. It must also to be expected that
some patients with vague clinical symptoms are tested
to rule out the diagnosis of LB rather than to confirm it.
In addition, the slight or non significant variation of the
monthly rates of seropositivity for both IgM and IgG
support the notion, that many patients had non-typical
clinical manifestations. The seasonal variation of seropo-
sitivity would have been more pronounced if more
straightforward cases of EM had been included.
It is possible that patients with clinical disease other
than LB may develop cross-reacting antibodies more fre-
quently than the healthy donor population, which was
used to adjust the specificity of the IgM antibody
ELISA. For all subgroups of patients in the present
study the rate of IgM seropositivity was at least 5.4%.
This may indicate that the finding of a solitary IgM
positive test in patients with non-distinct symptoms
should be interpreted with caution.
The selection of patients is assumed to be the impor-
tant factor for the rates of seropositivity and the results
obtained in this Danish study may not be directly
Table 2 Details of seropositivity in patients with a rash
and a tick bite
Bite lesion Number %IgM positive %treated
No rash No bite 1079 6 3
Other insect bite 137 4 7
Tick bite 416 8 14
Rash present No bite 389 19 36
Other insect bite 209 10 40
Tick bite 413 19 56
Three way table of the number of patients and% IgM seropositive according
to the combination of a reported rash and bite lesion.
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of LB, clinical practice, diagnostic methods, and recom-
mendations may differ. Nevertheless, low rates of sero-
positivity, and thus low pretest probability, in certain
patient groups may be a significant problem also in
other countries. It has been recommended that the pret-
est probability of LB should be no less than 0.20[1,12].
We are not aware of studies assessing whether this
recommendation is fulfilled in clinical practice. As
shown in this study, such a high rate of pretest probabil-
ity is probably not realistic when diagnosing e.g. Lyme
arthritis. Also contributing to the low rate of IgG sero-
positivity could be that the test has a lower sensitivity in
a consecutive stream of routine patients compared to
studies on selected well defined cases, as these studies
may have inherent problems with representativeness[5].
It is generally recommended to use a “confirmatory”
assay such as a Western blot (WB) in a two-tier
sequence in order to improve specificity[1,22]. However,
WB is difficult to standardize[24,25]and it has never
been evaluated on consecutive clinical samples, whether
this approach indeed improves the classification of
patients with and without active LB. The alternative
strategy is instead to use an assay with a strict cut-off
allowing only 2% false positives as assessed in the local
blood donor population for IgM and IgG antibody,
respectively. Healthy blood donors are assumed to
represent the lowest possible antibody reactivity in the
population. The flagella assay is designed in accordance
with this strategy and maintains an acceptable sensitiv-
ity. If using WB together with the flagella assay the cut-
off would need adjustment, otherwise the sensitivity
would become unacceptably low. No diagnostic labora-
tory in Denmark uses WB as a second line assay to
modify the specificity[26].
To our knowledge, this study is the first allowing a
crude assessment of the rate of false positive serological
tests in patients who are tested but do not have active
LB. We define an IgM or IgG antibody test to be falsely
positive if it occurs in a patient who does not have any
other indication of active LB. The maximum number of
false positives in excess of the healthy donor population
may be crudely estimated by subtracting 2% from rates
of seropositivity in Table 1. For example in the group of
patients with arthritis 3.4% are IgM positive in excess of
the healthy blood donors. The low rate of IgG seroposi-
tivity shows that Lyme arthritis is indeed rare. This
implies that the lowest total estimate of the specificity
for the IgM antibody test could be 94.6 percent instead
of the expected 98%.
False positive IgM results are documented to be com-
mon in patients with Epstein-Barr virus infection (54%)
and less so in patients with cytomegalovirus infection
(8%) [27]. These rates do, however, not pertain to
patients tested by general practitioners in the routine
clinical setting, and it would be misleading to include
them in a calculation of specificity. Moreover, these
viral infections do not follow the same seasonal trend as
LB where the large bulk of tests are carried out between
May and October (Figure 1A). By extensive analysis of
the current data we found no subgroup to fall below 5-
6% in IgM seropositivity during winter months (data not
shown) so the false rate could be estimated up to a
maximum of 5-6%. Concerning IgG antibodies there is
no indication that the specificity of IgG differs from
about 98%.
An interesting finding in this study is a nearly three-
fold difference in the rate of IgM (10.4%) seropositivity
compared to IgG (3.4%). This difference has not been
found in neither blood donors or from patients with
Lyme borreliosis [4,6-8]. One hypothesis for the high
frequency of IgM responses could be that many patients
with short duration of clinical Lyme borreliosis are
tested. Another hypothesis could be non-specific reac-
tions in patients with other diseases. The answer is most
likely a combination of both. The seasonal distribution
of the frequencies of samples and IgM responses sup-
port the hypothesis that true early Borrelia infections
contributes, at least partially, to the high IgM response.
The above interpretation of the rates of seropositivity
above rests on the important assumptions that low rates
of seropositivity indicate fewer and high rates indicate
more patients with active infection due to Borrelia burg-
dorferi even when some of the tested patients may have
non-specific antibody responses.
Still, the results obtained in this questionnaire-based
study may have important implications for the guide-
lines provided to general practitioners for interpretation
of serological tests for LB.
Conclusions
Low rates of seropositivity in certain patient groups
indicate a low pretest probability and accordingly there
is a notable risk of false positive results. 38% of all
patients were tested for suspected EM, although this is
not recommended due to the low sensitivity of the sero-
logical assay.
Appendix
Statistical issues
Choice of model
The regression models were used as a data mining/dis-
covery tool to search for groups of patients with higher
rates of seropositivity.
Model descriptions
Four multivariate models were built for the study:
Analysis of the complete dataset with response to sur-
vey as dependent variable was modelled using a
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probability of being included in the clinical survey:
logit Pi 299 152 Age 15 168 Age 15 5 SEX male () =+ () − () + () 00 00 0 .. * ,. * , * *. 0 032
The standard error is 0.12 for the children and 0.06
for the other estimates. The seasonal component was
chosen as the first half of the year (January to June)
compared with the second half (July to December).
Analysis of the seropositivity for IgG, IgM (= Positive)
and Treatment (= Yes) as dependent variables was mod-
elled using a logistic regression models with a smooth
function for the seasonal variation. The Generalized
additive model (GAM) developed by Simon Wood and
implemented in R [8] was chosen, as it is possible com-
bine both categorical and continuous variables into one
multivariate model. GAM is useful as non-parametric
smoothers may be fitted to the data without requiring
specification of a particular mathematical model to
describe the non-linearity. This type of model is an
extension of the generalized linear model and gives an
objective (non user chosen) description of the non-linear
data. This eliminates the need to choose stratification
into i.e. administrative units like calendar months which
are more indirectly related to the seasonal behaviour of
ticks or people. The syntax for the multivariate GAM-
model (IgM as an example) was:
Model1IgM gam IgMpos AGE SEX TICK2 EXPOSURE2
RASH EARLYNB
<− + + +
++
(~
+ ++
++ + + + +
LYMFOCYTOM CARDIT
ARTHRITIS ACA KNB VARIOUS NOCLINIC s PDA ATO4 bs cr
data klin2 family binomial
," " ,
,)
= ()
==
The variables (named as in the database) are in the
order corresponding to Table 1.
The syntax for the smooth term for the seasonal vari-
able was s(PDATO4,bs = “cr”)[8]. The results of the
model are stored in an R-object named “Model1IgM”.
The p-value for the smooth term (Figure 1. B, C and
1D) indicate whether the curved regression line departs
significantly from zero. The seasonal variable were
entered into the model as “day of the year” numbered
from 1 to 365 starting with January 1st according to the
date of the specimen, thus using the smallest available
unit for analysis. This does not correspond literally to
the data collection, which started from February to
April 2001 and ended in February to March 2002 with
some differences between the three laboratories. This
means that the data from February to April are the
combination of data from the same months in 2001 and
2002. In our experience the low total number of samples
received during winter and the rate of seropositivity is
similar from year to year (data not shown).
The GAM-models for IgG and treatment as depen-
dent variables were identical, except that there was no
positive IgG result among the few patients suspected of
carditis or lymphocytoma.
The age distribution of the rates of seropositivity was
initially examined by a non-linear GAM model prior to
c h o o s i n gt h em o r es i m p l ea g es t r a t i f i c a t i o ni nt h r e e
groups. The age distribution of Lyme disease/seroposi-
tivity with a higher frequency in children and older
adults has also been described previously [13].
127 patients had more than one symptom recorded
(e.g. both a rash and various symptoms). This issue has
not been considered separately. However, interaction
terms (* instead of +) between different variables were
tested in the model resulting in nonsignificant regres-
sion coefficients with large standard errors.
Abbreviations
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